Certara, Inc. announced it has acquired Applied BioMath, an industry-leader in providing model-informed drug discovery and development support to help accelerate and de-risk therapeutic research and development (R&D). Together, Certara and Applied BioMath are the life sciences industry’s largest team of experts in quantitative systems pharmacology (QSP), a method of biosimulation used across the development lifecycle to predict endpoints, biomarkers and the most effective dosing regimen.
Nine out of ten new therapies that enter the clinic do not achieve regulatory approval or commercialization primarily due to lack of efficacy or unmanageable toxicity. The popularity and prevalence of the QSP methodology has grown in recent years as a strategy to de-risk drug development. QSP combines computational modeling and experimental data to examine the relationships between a drug, the biological system, and the disease process. The resulting insights help scientists answer critical questions about novel therapies required for development progression including which patient populations are most likely to respond.
“Together, Applied BioMath and Certara have the scientific and computational expertise to industrialize QSP biosimulation methods,” said William F. Feehery, CEO of Certara. “Our respective QSP businesses are complementary with regards to clients, geographic location, indications and expertise. Additionally, Certara’s existing biosimulation and AI portfolios serve as accelerators for the combined team making QSP more widely available and accessible across the industry.”
“Certara’s track record of success increasing the adoption and scope of biosimulation solutions in life sciences is the ideal complement to our decade of QSP modeling experience and our proprietary QSP platform,“ said John Burke, Applied BioMath’s CoFounder, President and CEO. “The opportunity to establish the largest team of interdisciplinarian QSP scientists is exciting for the Applied BioMath team as it helps us achieve our mission of revolutionizing drug invention faster.”
The newly formed QSP center of excellence further supports drug developers in the following ways.
- Increased Scale – Together both teams will be industrializing QSP for more types of development to enable a more efficient and insightful drug development process.
- Seamless Biosimulation Across Development: With numerous synergies between QSP and other types of biosimulation, the combined portfolio enhances decision-making at every stage, from preclinical research to later phase development.
- Biology-Focused Drug Development: As drug development becomes more biology-focused, the combined team will build more reusable models to optimize novel and combination therapies for groundbreaking results.
Certara accelerates medicines using biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,300 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries.
SOURCE: GlobeNewswire